Article

Researchers Discover Cause of Arterial Inflammation in Atherosclerosis

Researchers from Imperial College London have found the trigger that causes inflammation and artery damage in patients with atherosclerosis.

Researchers from Imperial College London have found the trigger that causes inflammation and artery damage in patients with atherosclerosis. According to a press release, the trigger is the receptor molecule TLR-2, which “lives on the surface of an immune cell,” switching it into “attack mode” in the presence of harmful molecules and stress. Research shows that TLR-2 “is unusually active in plaques in the carotid artery in the neck,” and that blocking the TLR-2 receptor prevents cells from producing molecules that cause inflammation and damage to the artery.

Study author Claudia Monaco, MD, PhD, from the Kennedy Institute of Rheumatology and Vascular Surgery at Imperial College London, said that this study “reveals the trigger for inflammation and tissue breakdown in artery plaques. We have also shown that this trigger mechanism can be blocked using antibodies. If we can find a way to successfully block these receptors in people, without reducing their ability to fight off infection, we could potentially develop a treatment for atherosclerosis.”

For the study, researchers assessed atherosclerotic sections of the carotid artery from 58 patients who had suffered a stroke. Analysis of the artery tissue showed that “the cells had produced an unusually large amount of inflammatory molecules and enzymes that damage arteries.”

The researchers cultivated the cells with “several different antibodies designed to block different receptors and molecules involved in the inflammation process,” revealing that “blocking TLR-2 using an antibody reduced the production of inflammation molecules and enzymes dramatically.”

Results from the study were published online ahead of print in Circulation. In the article abstract, the authors noted that a

dominant-negative form of myeloid differentiation primary response gene 88 (MyD88) decreased the production of monocyte chemotactic protein-1/CCL2, IL-8/CXCL8, IL-6, matrix metalloproteinase-1 (MMP-1), and MMP-3, as well as nuclear factor-kappaB activation in atheroma cell cultures. IL-1R antagonist, TLR-4 blocking antibodies, or overexpression of a dominant-negative form of the TLR-4 signaling adaptor TRIF-related adaptor molecule “reduced nuclear factor- kappaB activity but did not have a broad impact on the production of the mediators studied.” In contrast, TLR-2 neutralizing antibodies “inhibited nuclear factor-kappaB activation and significantly reduced monocyte chemotactic protein-1/CCL2, IL-8/CXCL8, IL-6, and MMP-1, MMP-2, MMP-3, and MMP-9 production.”

Related Videos
Yehuda Handelsman, MD: Insulin Resistance in Cardiometabolic Disease and DCRM 2.0 | Image Credit: TMIOA
Nathan D. Wong, MD, PhD: Growing Role of Lp(a) in Cardiovascular Risk Assessment | Image Credit: UC Irvine
Laurence Sperling, MD: Expanding Cardiologists' Role in Obesity Management  | Image Credit: Emory University
Laurence Sperling, MD: Multidisciplinary Strategies to Combat Obesity Epidemic | Image Credit: Emory University
Matthew J. Budoff, MD: Examining the Interplay of Coronary Calcium and Osteoporosis | Image Credit: Lundquist Institute
Orly Vardeny, PharmD: Finerenone for Heart Failure with EF >40% in FINEARTS-HF | Image Credit: JACC Journals
Matthew J. Budoff, MD: Impact of Obesity on Cardiometabolic Health in T1D | Image Credit: The Lundquist Institute
Matthew Weir, MD: Prioritizing Cardiovascular Risk in Chronic Kidney Disease | Image Credit: University of Maryland
Erin Michos, MD: HFpEF in Women and Sex-Specific Therapeutic Approaches | Image Credit: Johns Hopkins
© 2024 MJH Life Sciences

All rights reserved.